Health and Fitness Health and Fitness
Tue, October 4, 2011
Mon, October 3, 2011
[ Mon, Oct 03rd 2011 ] - Market Wire
Medwell Capital to Adopt IFRS
Sun, October 2, 2011
Sat, October 1, 2011
Fri, September 30, 2011
Thu, September 29, 2011
Wed, September 28, 2011
Tue, September 27, 2011
Mon, September 26, 2011
Sat, September 24, 2011
Fri, September 23, 2011
Thu, September 22, 2011
Wed, September 21, 2011
Tue, September 20, 2011
Mon, September 19, 2011
Sun, September 18, 2011
Sat, September 17, 2011
Fri, September 16, 2011
Thu, September 15, 2011
Wed, September 14, 2011
Tue, September 13, 2011
Mon, September 12, 2011
Sun, September 11, 2011
Sat, September 10, 2011
Fri, September 9, 2011
Thu, September 8, 2011
Wed, September 7, 2011

Cerus to Present at Jefferies 2011 Global Healthcare Conference on Sept 28, 2011


//health-fitness.news-articles.net/content/2011/ .. lobal-healthcare-conference-on-sept-28-2011.html
Published in Health and Fitness on Wednesday, September 21st 2011 at 5:36 GMT by Market Wire   Print publication without navigation


CONCORD, Calif.--([ BUSINESS WIRE ])--Cerus Corporation (NASDAQ:CERS) announced today that William aObia Greenman, president and chief executive officer, is scheduled to present a corporate update at the Jefferies 2011 Global Healthcare Conference in London at 8:00 AM BST (3:00 AM EST) on Wednesday, September 28, 2011.

A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at [ http://investor.cerus.com ]. A replay will be available for approximately two weeks following the completion of the event.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See [ http://www.cerus.com ] for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.


Publication Contributing Sources